ArticleMediterranean journal of hematology and infectious diseases2019
Soluble ST2 and CD163 as Potential Biomarkers to Differentiate Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome.
Article in Mediterranean journal of hematology and infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis/macrophage activation syndrome - a systematic review.Clinical and experimental immunology · 2021Pooled it
- Coordinated expansion of CD163bioRxiv : the preprint server for biology · 2026Article
- Assessment of Hemophagocytic Lympho-Histiocytosis (HLH) in the Setting of Adult Acute Liver Failure.Journal of viral hepatitis · 2025Article
- Biomarkers for an early diagnosis of immune effector cell associated-hemophagocytic syndrome.Frontiers in immunology · 2025Article
- Scavenger receptors: key players in the immunological puzzle of lupus.Frontiers in lupus · 2025Article
- An antibody to IL-1 receptor 7 protects mice from LPS-induced tissue and systemic inflammation.Frontiers in immunology · 2024Article
- Genetic and clinical characteristics of primary hemophagocytic lymphohistiocytosis in children.Annals of hematology · 2024Review
- Proteomic Analysis of Pediatric Hemophagocytic Lymphohistiocytosis: a Comparative Study with Healthy Controls, Sepsis, Critical Ill, and Active Epstein-Barr virus Infection to Identify Altered Pathways and Candidate Biomarkers.Journal of clinical immunology · 2023Article
- Lung Expression of Macrophage Markers CD68 and CD163, Angiotensin Converting Enzyme 2 (ACE2), and Caspase-3 in COVID-19.Medicina (Kaunas, Lithuania) · 2023Article
- Postpartum fevers, a rare presentation of secondary hemophagocytic lymphohistiocytosis.Clinical case reports · 2023Article
- From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry.Antibodies (Basel, Switzerland) · 2021Article
- Do COVID-19 Infections Result in a Different Form of Secondary Hemophagocytic Lymphohistiocytosis.International journal of molecular sciences · 2021Review
- COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.Immunologic research · 2020Review
- [Clinical significance of secondary hemophagocytic lymphohistiocytosis with pleural effusion].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- The IL-1 family of cytokines and receptors in rheumatic diseases.Nature reviews. Rheumatology · 2019Review
- A novel anti-human IL-1R7 antibody reduces IL-18-mediated inflammatory signaling.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The differentiation of primary hemophagocytic lymphohistiocytosis (pHLH) and macrophage activation syndrome (MAS) poses a challenge to hematologists. The aim of this study was (1) to compare the levels of soluble ST2 (sST2), sCD163, IFN-γ, IL-10, IL-18, TNF-α and Serum soluble interleukin-2 receptor (sCD25) in patients with pHLH and MAS and (2) to investigate whether they can help differentiate the two diseases. A total of 52 participants were recruited in this study, including 12 pHLH patients, 20 MAS patients, and 20 healthy subjects. We measured the levels of sST2, sCD163 and sCD25 in serum by ELISA. The serum levels of IFN-γ, IL-10, IL-18, and TNF-α were detected using a Luminex 200 instrument. The serum levels of sST2 and sCD163 in MAS patients were markedly higher than that in pHLH patients (363.13 ± 307.24 ng/ml vs 80.75 ± 87.04 ng/ml,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.